PPMD Provides Testimony During FDA CBER Meeting on Patient Perspectives on Gene Therapy Products
Earlier this week, Chief Advocacy Officer Ryan Fischer addressed the FDA’s Center for Biologics Evaluation and Research (CBER) Office of Tissues and Advanced Therapies (OTAT) at a Public Patient-Focused Drug Development (PFDD) Meeting on Patient…Learn More